Abivertinib maleate is under clinical development by Sorrento Therapeutics and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Abivertinib maleate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abivertinib maleate overview
Abivertinib maleate (AC-0010) is under development for the treatment of metastatic non small cell lung cancer, relapsed and refractory chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and other Non-Hodgkin B-Cell lymphoma such as follicular lymphoma, marginal zone lymphoma, acute respiratory distress syndrome (ARDS) in hospitalized COVID patients, Burkitt lymphoma, Waldenstrom macroglobulinemia and COVID-19 pneumonia caused by the severe acute coronavirus 2 (SARS-COV2). The drug candidate is administered through oral route in the form of capsule. The drug candidate is developed based on xCELLigence biosensor technology and proprietary small molecule library technology. It targets epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK).
It was also under development for multiple sclerosis, graft versus host disease, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer.
Sorrento Therapeutics overview
Sorrento Therapeutics (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works in collaboration with biopharmaceutical companies and academic institutions to develop novel immunotherapies. Sorrento is headquartered in San Diego, California, the US.
For a complete picture of Abivertinib maleate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Abivertinib Maleate in Acute Respiratory Distress Syndrome
Premium Insights
The gold standard of business intelligence.
